文献速递造血干细胞移植与细胞治疗

阿那白滞素治疗ICANS后早期神经反应预测结局

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.
PubMed 文献 · Blood Adv · 2026-01-01

该研究回顾性分析了101例接受阿那白滞素治疗的ICANS患者(其中90例为激素难治性),评估疗效及预测因素。结果显示28天ICANS缓解累积发生率为86%,治疗相关死亡率为13%,72小时内显著神经改善(SNI)与更快的ICANS缓解和出院、更低的激素暴露及TRM相关。

要点

  • 72小时内SNI与更快的ICANS缓解(中位3 vs 9天)和出院(28天累积发生率93% vs 53%)相关。
  • 高龄、CAR-T产品类型和较高第0天CRP与72小时SNI几率降低独立相关。

核心结论

  • 阿那白滞素治疗ICANS后,72小时SNI可作为识别需额外治疗患者的实用临床决策点。

研究设计与样本

  • 回顾性研究,纳入101例接受阿那白滞素治疗的ICANS患者,其中激素难治性90例。

主要发现

  • 从阿那白滞素开始至ICANS缓解的中位时间为8天,28天ICANS缓解累积发生率为86%,TRM为13%。
  • 阿那白滞素治疗失败率为28%,第+28天抗肿瘤缓解率为91%(完全缓解47%)。
  • 43%的患者在阿那白滞素开始后72小时内达到SNI(ICANS改善≥2级)。

临床怎么用

  • 对于ICANS患者,阿那白滞素治疗后72小时评估神经改善程度,若未达到SNI(≥2级改善)可考虑需额外治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anakinra is increasingly used for corticosteroid-refractory and/or severe immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T-cell therapy; however, robust data on its efficacy and predictors of response are lacking. We evaluated the outcomes of 101 patients treated with anakinra for ICANS (corticosteroid-refractory, n = 90) and investigated factors associated with anakinra efficacy. The median time to ICANS resolution from anakinra initiation was 8 days, and the 28-day cumulative incidences of ICANS resolution and treatment-related mortality (TRM) were 86% and 13%, respectively. Anakinra treatment failure occurred in 28%. The day +28 antitumor response rate was 91% (complete response, 47%). Significant neurologic improvement (SNI; ≥2-grade improvement in ICANS) occurred in 43% of patients within 72 hours after anakinra initiation. Achieving 72-hour SNI was associated with faster time to ICANS resolution (median, 3 vs 9 days; P< .001) and hospital discharge (28-day cumulative incidence, 93% vs 53%; P< .001), lower 2-week cumulative exposure to dexamethasone (120 vs 190 mg; P = .029) and anakinra (3650 vs 6600 mg; P = .059), lower TRM (28-day cumulative incidence, 0% vs 21%; P = .011), and a trend toward superior overall survival (28 days, 98% vs 74%; P = .094). In multivariable analysis, older age, CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI. Our study benchmarks key clinical outcomes after anakinra treatment for ICANS; 72-hour SNI may provide a practical clinical decision point to identify patients who may require additional treatment strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Liang EC, Kungwankiattichai S, Wu X, et al. Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome. Blood Adv. 2026. PMID: 42530978. doi:10.1182/bloodadvances.2026020103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。